title: Intravenous fluid therapy successfully prevents renal injury by gemcitabine in patients with pancreatic cancer.
authors.forename: Shigeru B H
authors.initials: SB
authors.lastname: Ko
authors.forename: Sakiko
authors.initials: S
authors.lastname: Azuma
authors.forename: Kaori
authors.initials: K
authors.lastname: Kamimura
authors.forename: Hidemi
authors.initials: H
authors.lastname: Goto
authors.forename: Naohiko
authors.initials: N
authors.lastname: Anzai
authors.forename: Akiko
authors.initials: A
authors.lastname: Yamamoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ishiguro
authors.forename: Nobumasa
authors.initials: N
authors.lastname: Mizuno
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003460:Crystallization; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D005440:Fluid Therapy / Q000379:methods; D006801:Humans; D007262:Infusions, Intravenous; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D003841:Deoxycytidine; D000093542:Gemcitabine